Teresa M. Frasconi
A5081764960- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Phagocytosis and Immune Regulation
- RNA Interference and Gene Delivery
- Cancer Immunotherapy and Biomarkers
- Eosinophilic Esophagitis
- Pancreatic function and diabetes
- Acute Myeloid Leukemia Research
- IL-33, ST2, and ILC Pathways
- CRISPR and Genetic Engineering
- Monoclonal and Polyclonal Antibodies Research
- Virus-based gene therapy research
Molecular Partners (Switzerland)
2022-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2024
European Institute of Oncology
2024
University Hospital Bonn
2024
Abstract The prognosis of patients with acute myeloid leukemia (AML) is limited, especially for elderly or unfit not eligible hematopoietic stem cell (HSC) transplantation. disease driven by leukemic cells (LSCs), which are characterized clonal heterogeneity and resistance to conventional therapy. These therefore believed be a major cause progression relapse. We designed MP0533, multispecific CD3-engaging ankyrin repeat protein (DARPin) that can simultaneously bind three antigens on AML...
The lysine-specific histone demethylase 1 A (LSD1) is involved in antitumor immunity; however, its role shaping CD8 + T cell (CTL) differentiation and function remains largely unexplored. Here, we show that pharmacological inhibition of LSD1 (LSD1i) CTL the context adoptive therapy (ACT) elicits phenotypic functional alterations, resulting a robust immunity preclinical models female mice. In addition, combination anti-PDL1 treatment with LSD1i-based ACT eradicates tumor leads to long-lasting...
Chronic inflammasome activation in mononuclear phagocytes (MNPs) promotes fibrosis various tissues, including the kidney. The cellular and molecular links between are unclear. To address this question, we fed mice lacking immunological mediators an adenine-enriched diet, which causes crystal precipitation renal tubules, crystal-induced activation, fibrosis. We found that kidney depended on intrarenal inflammasome-dependent type 3 immune response driven by its signature transcription factor...
<div>Abstract<p>The prognosis of patients with acute myeloid leukemia (AML) is limited, especially for elderly or unfit not eligible hematopoietic stem cell (HSC) transplantation. The disease driven by leukemic cells (LSCs), which are characterized clonal heterogeneity and resistance to conventional therapy. These therefore believed be a major cause progression relapse. We designed MP0533, multispecific CD3-engaging ankyrin repeat protein (DARPin) that can simultaneously bind...
<div>Abstract<p>The prognosis of patients with acute myeloid leukemia (AML) is limited, especially for elderly or unfit not eligible hematopoietic stem cell (HSC) transplantation. The disease driven by leukemic cells (LSCs), which are characterized clonal heterogeneity and resistance to conventional therapy. These therefore believed be a major cause progression relapse. We designed MP0533, multispecific CD3-engaging ankyrin repeat protein (DARPin) that can simultaneously bind...
<p>Supplementary Fig. S12.</p>
<p>Supplementary Fig. S1. MP0533 format comparison.</p>
<p>Supplementary Fig. S12.</p>
<p>Supplementary Fig. S16. Binding to HUVEC cells.</p>
<p>Supplementary Fig. S2. MP0533 affinity traces and simultaneous binding to its targets.</p>
<p>Supplementary Fig. S15. TCE-induced CD70 upregulation on activated CD4 and CD8 T cells. Expression of cells in cocultures with MOLM-13 1 nmol/L MP0533 or CD123-CD3 DART.</p>
<p>Supplementary Fig. S2. MP0533 affinity traces and simultaneous binding to its targets.</p>
<p>Supplementary Fig. S3. TAA quantification on healthy blood cells.</p>
<p>Supplementary Fig. S5. TAA expression on AML and healthy donor samples.</p>
<p>Supplementary Fig. S5. TAA expression on AML and healthy donor samples.</p>
<p>Supplementary Fig. S16. Binding to HUVEC cells.</p>
<p>Supplementary Fig. S13. MP0533 safety profile in hPBMC mouse model xenografted intravenously with MOLM-13 cells.</p>
<p>Supplementary Fig. S1. MP0533 format comparison.</p>
<p>Supplementary Fig. S17. TAA expression analysis on AML PDX cells.</p>
<p>Supplementary Fig. S10. Competition/inhibition with soluble ligands/TAAs.</p>
<p>Supplementary Fig. S14. Killing of healthy cells.</p>
<p>Supplementary Fig. S4. MP0533 induces similar low cytokine release with pan T or PBMC as effector cells.</p>
<p>Supplementary Fig. S4. MP0533 induces similar low cytokine release with pan T or PBMC as effector cells.</p>
<p>Supplementary Fig. S18. Combination with SOC.</p>